2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]
Oral gonorrhea antibiotic Nuzolvence approved just weeks ago The Food and Drug Administration recently approved Nuzolvence (zoliflodacin) as a first‑in‑class...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)







